… Starton”), a clinical-stage biotechnology company transforming standard-of- … STAR-LLD to Revlimid® demonstrated the drug is well … so people with cancer can receive continuous treatment to live … current and future clinical trials, constitute “forward-looking …

… daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (Decadron) … and BENEFIT (NCT04751877) trials, Chari expressed concerns … treatment philosophy: for transplant-ineligible populations, the number of drugs … label, phase 3 trial. Lancet. 2017; …

… address unmet medical needs in areas like gastric cancer and … 's expectations for pharmaceutical-specific tariffs. Still, Bristol … sales forecasts for the treatment.   The company is banking … from a year earlier. Revlimid, a drug used to treat adults …

… study testing the drug as an adjunctive treatment to atypicals in … including seven phase 3 trials for Cobenfy across three … medicines, the analyst team at William Blair noted that Revlimid’ … account for any potential pharmaceutical tariffs, the William Blair …

… average analyst estimate.  The drug’s success is imperative … blood cancer treatment Revlimid. Two of its other top-selling medicines, the blood … nearly 400-person clinical trial just found Cobenfy was … policies. The U.S. pharmaceutical industry has so far …

… Know. Promisingly, its new schizophrenia treatment, Cobenfy, generated better-than- … of cancer drugs Opdivo and Yervoy beat expectations, as did generics-facing Revlimid … heart disease treatment that also recently faced a clinical trial setback. Sotyktu …

… . started a probe into the pharmaceutical sector earlier this month as … of potential tariffs targeting the pharmaceutical industry, and that Bristol Myers … shares with Pfizer, and blood cancer drug Revlimid fell less than expected. The …

… Cobenfy as an adjunctive treatment to atypical antipsychotics failed to … symptoms. Approved by the FDA to treat schizophrenia in … Arise trial marks another blow to BMS’ new drug portfolio in … key legacy brands, including Revlimid, Pomalyst, Opdivo and Pfizer …

… CancerNetwork® hosted a panel discussion focused on CD38 monoclonal antibody treatment … of daratumumab plus lenalidomide (Revlimid) as maintenance therapy … , MD, professor of medicine at Duke University School … IMROZ led to FDA approval for 4 drugs, including a …

… in patients with lenalidomide (Revlimid)–refractory multiple myeloma and … phase 3 CARTITUDE-4 trial (NCT04181827).1 The findings … for Research and Treatment of Cancer QOL Questionnaire Core … inhibitor and an immunomodulatory drug—and who are refractory …